How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis)-Reference-Cited by-同舟云学术

How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis)

Published:2020-11 Issue:11 Volume:20 Page:e826-e831
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Chaulagain Chakra P.^ORCID,Herlitz Leal C.,Fu Julie^ORCID,Bilani Nadeem^ORCID,Lucitt Camerun,Comenzo Raymond L.

Funder

Maroone Cancer Center

Cleveland Clinic Florida

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference20 articles.

1. Primary systemic amyloidosis: clinical and laboratory features in 474 cases;Kyle;Semin Hematol,1995

2. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis;Nasr;Kidney Int,2013

3. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases;Said;Clin J Am Soc Nephrol,2013

4. Case of T-cell large granular lymphocytic leukemia and renal immunoglobulin heavy chain amyloidosis;Fu;Am J Case Rep,2019

5. The root of many evils: indolent large granular lymphocyte leukemia and associated disorders;Zhang;Hematol Oncol,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case of μ Heavy and λ Light Chain Amyloidosis in a Patient With Bi-Clonal (IgM κ and λ) Gammopathy Treated With Daratumumab;Cureus;2024-03-26

2. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment;American Journal of Hematology;2023-12-14

3. Cardiac Amyloidosis: A Contemporary Review of Medical and Surgical Therapy;Current Cardiology Reviews;2023-10-04

4. Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment;Journal of the National Comprehensive Cancer Network;2023-01

5. Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients;Onkologie;2022-10-14